6-甲基-[1,2,4]噻唑并[4,3-a]嘧啶 | 65267-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 中文名称: 6-甲基-[1,2,4]噻唑并[4,3-a]嘧啶
• 英文名称: 6-Methyl-s-triazolo<4,3-a>pyrimidin
• 英文别名: 6-methyl-[1,2,4]triazolo[4,3-a]pyrimidine；6-Methyl-[1,2,4]triazolo[4,3-a]pyrimidine
• CAS: 65267-47-2
• 化学式: C₆H₆N₄
• mdl: MFCD09994392
• 分子量: 134.14
• InChiKey: XGURBWVYOBTWHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089355A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE αV
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089357A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（Ia）或（Ib）的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αV-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及使用这些化合物和药物组合物治疗与αV-含有整合素失调相关的疾病、紊乱或状况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] AMIDES DE PYRROLE EN TANT QU'INHIBITEURS D'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089360A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了具有式（I）的化合物或其立体异构体、互变异构体、或其药用可接受的盐或溶剂，其中所有变量均如本文所定义。这些化合物是αv-含有整合素的抑制剂。本发明还涉及包含这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，例如病理纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] ACIDES PROPIONIQUES À SUBSTITUTION EN POSITION 3 EN TANT QU'INHIBITEURS D'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089353A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αν- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay- containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了化合物的公式(I)：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αν-含有整合素的拮抗剂。本发明还涉及包含这些化合物的药物组合物和使用这些化合物和药物组合物来治疗与ay-含有整合素失调相关的疾病、疾病或症状的方法，例如病理纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] BENZOPYRAZOLE COMPOUND<br/>[FR] COMPOSÉ BENZOPYRAZOLE<br/>[ZH] 苯并吡唑类化合物
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2021136429A1

  公开（公告）日：2021-07-08

  苯并吡唑类化合物，具体公开了式(I)所示化合物及其药学上可接受的盐